Latest & greatest articles for liraglutide

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on liraglutide or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on liraglutide and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for liraglutide

22. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial.

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. BACKGROUND: Liraglutide 3·0 mg was shown to reduce bodyweight and improve glucose metabolism after the 56-week period of this trial, one of four trials in the SCALE programme. In the 3-year assessment of the SCALE Obesity and Prediabetes trial we aimed to evaluate the proportion of individuals with prediabetes who were diagnosed (...) with type 2 diabetes. METHODS: In this randomised, double-blind, placebo-controlled trial, adults with prediabetes and a body-mass index of at least 30 kg/m2, or at least 27 kg/m2 with comorbidities, were randomised 2:1, using a telephone or web-based system, to once-daily subcutaneous liraglutide 3·0 mg or matched placebo, as an adjunct to a reduced-calorie diet and increased physical activity. Time to diabetes onset by 160 weeks was the primary outcome, evaluated in all randomised treated individuals

Lancet2017

23. Xultophy (insulin degludec and liraglutide) - type 2 diabetes

Xultophy (insulin degludec and liraglutide) - type 2 diabetes Xultophy® (insulin degludec and liraglutide) × Insert searchphrase to search the website Insert searchphrase to search the website > > > Xultophy® (insulin degludec and liraglutide) Conclusion Xultophy® (insulin degludec and liraglutide) is a combination product for treatment of type 2 diabetes administered by one daily injection consisting of insulin degludec and the GLP-1 receptor agonist (GLP1-RA) liraglutide. The dose (...) is administered by a pre-filled injection pen with a fixed-ratio combination of insulin degludec and liraglutide, which offers a less flexible dose adjustment. The maximum daily dose is 50 dose steps corresponding to 50 units insulin degludec/1.8 mg liraglutide. In clinical studies, Xultophy has been demonstrated to reduce HbA1c more than both insulin degludec, liraglutide and insulin glargin in combination with existing treatment with different oral antidiabetics. Compared to the above-mentioned insulins

Danish Pharmacotherapy Reviews2017

24. Randomised controlled trial: Liraglutide, a GLP-1 receptor agonist, prevents cardiovascular outcomes in patients with type 2 diabetes

Randomised controlled trial: Liraglutide, a GLP-1 receptor agonist, prevents cardiovascular outcomes in patients with type 2 diabetes Liraglutide, a GLP-1 receptor agonist, prevents cardiovascular outcomes in patients with type 2 diabetes | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name (...) or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Liraglutide, a GLP-1 receptor agonist, prevents cardiovascular outcomes in patients with type 2 diabetes Article Text Therapeutics/Prevention Randomised controlled trial Liraglutide, a GLP-1 receptor agonist, prevents cardiovascular outcomes in patients with type 2 diabetes

Evidence-Based Medicine (Requires free registration)2017

26. Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: a 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial

Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: a 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial 27585605 2016 09 02 2016 12 07 1935-5548 39 11 2016 Nov Diabetes care Diabetes Care Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. 2042-2050 To investigate effects (...) of dipeptidyl peptidase-4 inhibitor (DPP-4I) sitagliptin or glucagon-like peptide 1 (GLP-1) receptor agonist liraglutide treatment on renal hemodynamics, tubular functions, and markers of renal damage in overweight patients with type 2 diabetes without chronic kidney disease (CKD). In this 12-week, randomized, double-blind trial, 55 insulin-naïve patients with type 2 diabetes (mean ± SEM: age 63 ± 7 years, BMI 31.8 ± 4.1 kg/m(2), glomerular filtration rate [GFR] 83 ± 16 mL/min/1.73 m(2); median

EvidenceUpdates2016

27. Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes (LIRA-SWITCH): a randomized, double-blind, double-dummy, active-controlled 26-week trial

Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes (LIRA-SWITCH): a randomized, double-blind, double-dummy, active-controlled 26-week trial 27381275 2016 09 14 2017 02 20 1463-1326 18 12 2016 Dec Diabetes, obesity & metabolism Diabetes Obes Metab Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes (LIRA-SWITCH): a randomized, double-blind, double-dummy, active-controlled 26-week trial. 1191-1198 10.1111 (...) /dom.12736 To confirm superiority on glycaemic control by switching from sitagliptin to liraglutide 1.8 mg/d versus continued sitagliptin. A randomized, multicentre, double-blind, double-dummy, active-controlled trial across 86 office- or hospital-based sites in North America, Europe and Asia. Subjects with type 2 diabetes who had inadequate glycaemic control (glycated haemoglobin [HbA1c] 7.5-9.5% on sitagliptin (100 mg/d) and metformin (≥1500 mg daily) for ≥90 days were randomized to either switch

EvidenceUpdates2016

28. Liraglutide (Victoza)

Liraglutide (Victoza) Liraglutide | CADTH.ca Find the information you need Liraglutide Liraglutide Last Updated: September 21, 2016 Result type: Reports Project Number: SR0505-000 Product Line: Generic Name: Liraglutide Brand Name: Victoza Manufacturer: Novo Nordisk Canada Inc. Indications: Diabetes Mellitus, Type 2 Submission Type: Resubmission Project Status: Withdrawn Files Follow us: © 2017 Canadian Agency for Drugs and Technologies in Health Get our newsletter:

Canadian Agency for Drugs and Technologies in Health - Common Drug Review2016

29. Liraglutide (Victoza) - type 2 diabetes mellitus

Liraglutide (Victoza) - type 2 diabetes mellitus Published 12 September 2016 Statement of Advice: liraglutide (Victoza ® ) 6 mg/ml solution for injection in pre-filled pen (No: 1192/16) Novo Nordisk Limited 05 August 2016 ADVICE: in the absence of a submission from the holder of the marketing authorisation liraglutide (Victoza ® ) is not recommended for use within NHS Scotland. Indication under review: As monotherapy for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic

Scottish Medicines Consortium2016

30. Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial

Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial 27506222 2016 09 23 2016 09 23 1935-5548 39 10 2016 Oct Diabetes care Diabetes Care Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial. 1702-10 10.2337/dc16-0691 To investigate whether liraglutide added to treat-to-target insulin improves glycemic control and reduces insulin requirements (...) and body weight in subjects with type 1 diabetes. A 52-week, double-blind, treat-to-target trial involving 1,398 adults randomized 3:1 to receive once-daily subcutaneous injections of liraglutide (1.8, 1.2, or 0.6 mg) or placebo added to insulin. HbA1c level was reduced 0.34-0.54% (3.7-5.9 mmol/mol) from a mean baseline of 8.2% (66 mmol/mol), and significantly more for liraglutide 1.8 and 1.2 mg compared with placebo (estimated treatment differences [ETDs]: 1.8 mg liraglutide -0.20% [95% CI -0.32

EvidenceUpdates2016

31. Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: the ADJUNCT TWO Randomized Trial

Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: the ADJUNCT TWO Randomized Trial 27493132 2016 09 23 2016 09 23 1935-5548 39 10 2016 Oct Diabetes care Diabetes Care Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial. 1693-701 10.2337/dc16-0690 To investigate the efficacy and safety of liraglutide added to capped insulin doses in subjects with type (...) 1 diabetes. A 26-week, placebo-controlled, double-blind, parallel-group trial enrolling 835 subjects randomized 3:1 receiving once-daily subcutaneous liraglutide (1.8, 1.2, and 0.6 mg) or placebo added to an individually capped total daily dose of insulin. Mean baseline glycated hemoglobin (HbA1c) (8.1% [65.0 mmol/mol]) was significantly decreased with liraglutide versus placebo at week 26 (1.8 mg: -0.33% [3.6 mmol/mol]; 1.2 mg: -0.22% [2.4 mmol/mol]; 0.6 mg: -0.23% [2.5 mmol/mol]; placebo: 0.01% [0.1 mmol

EvidenceUpdates2016

32. Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.

Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. IMPORTANCE: Abnormal cardiac metabolism contributes to the pathophysiology of advanced heart failure with reduced left ventricular ejection fraction (LVEF). Glucagon-like peptide 1 (GLP-1) agonists have shown cardioprotective effects in early clinical studies of patients with advanced heart failure, irrespective of type 2 diabetes status. OBJECTIVE (...) : To test whether therapy with a GLP-1 agonist improves clinical stability following hospitalization for acute heart failure. DESIGN, SETTING, AND PARTICIPANTS: Phase 2, double-blind, placebo-controlled randomized clinical trial of patients with established heart failure and reduced LVEF who were recently hospitalized. Patients were enrolled between August 2013 and March 2015 at 24 US sites. INTERVENTIONS: The GLP-1 agonist liraglutide (n = 154) or placebo (n = 146) via a daily subcutaneous injection

JAMA2016

33. Efficacy and safety of once-weekly glucagon-like peptide-1 receptor agonists compared with exenatide and liraglutide in type 2 diabetes: a systemic review of randomised controlled trials

Efficacy and safety of once-weekly glucagon-like peptide-1 receptor agonists compared with exenatide and liraglutide in type 2 diabetes: a systemic review of randomised controlled trials 27456750 2016 07 28 2017 02 08 1742-1241 70 8 2016 Aug International journal of clinical practice Int. J. Clin. Pract. Efficacy and safety of once-weekly glucagon-like peptide-1 receptor agonists compared with exenatide and liraglutide in type 2 diabetes: a systemic review of randomised controlled trials. 649 (...) -56 10.1111/ijcp.12847 Once-weekly glucagon-like peptide-1 receptor agonists (GLP-1RAs) have shown promising results in the treatment of type 2 diabetes. Herein, we compared the efficacy and safety of once-weekly GLP-1RAs with exenatide and liraglutide separately. We systematically surveyed the pertinent literature using various databases. The randomised controlled trials that compared once-weekly GLP-1RAs with exenatide and liraglutide in type 2 diabetes were included. Our main end-points were

EvidenceUpdates2016

34. Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial

Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial 27311491 2016 08 24 2016 08 24 1935-5548 39 9 2016 Sep Diabetes care Diabetes Care Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial. 1501-9 10.2337/dc15-2479 To compare the efficacy and safety of liraglutide versus lixisenatide as add-on to metformin in patients (...) with type 2 diabetes not achieving adequate glycemic control on metformin alone. In this 26-week, randomized, parallel-group, open-label trial, 404 patients were randomized 1:1 to liraglutide 1.8 mg or lixisenatide 20 µg as add-on to metformin. Liraglutide was administered once daily at any time of the day. Lixisenatide was administered once daily within 1 h prior to the morning or evening meal. At week 26, liraglutide reduced HbA1c (primary end point) more than lixisenatide (estimated treatment difference -0.62

EvidenceUpdates2016

35. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. BACKGROUND: The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown. METHODS: In this double-blind trial, we randomly assigned patients with type 2 diabetes and high cardiovascular risk to receive liraglutide or placebo. The primary composite outcome in the time-to-event analysis was the first occurrence of death from cardiovascular (...) causes, nonfatal myocardial infarction, or nonfatal stroke. The primary hypothesis was that liraglutide would be noninferior to placebo with regard to the primary outcome, with a margin of 1.30 for the upper boundary of the 95% confidence interval of the hazard ratio. No adjustments for multiplicity were performed for the prespecified exploratory outcomes. RESULTS: A total of 9340 patients underwent randomization. The median follow-up was 3.8 years. The primary outcome occurred in significantly fewer

NEJM2016

36. Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26-week, open-label, randomised, active comparator clinical trial

Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26-week, open-label, randomised, active comparator clinical trial 27060930 2016 07 13 2017 02 20 1463-1326 18 8 2016 Aug Diabetes, obesity & metabolism Diabetes Obes Metab Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26-week, open-label, randomized, active comparator (...) clinical trial. 803-11 10.1111/dom.12674 To compare the efficacy and safety of liraglutide versus sitagliptin as add-on to metformin after 26 weeks of treatment in Chinese patients with type 2 diabetes mellitus (T2DM). This 26-week open-label, active comparator trial (NCT02008682) randomized patients (aged 18-80 years) with T2DM inadequately controlled with metformin [glycated haemoglobin (HbA1c) 7.0-10.0% (53-86 mmol/mol)] 1 : 1 to once-daily subcutaneously administered liraglutide 1.8 mg (n = 184

EvidenceUpdates2016

37. Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial.

Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial. 26934259 2016 03 03 2016 03 08 2016 10 17 1538-3598 315 9 2016 Mar 01 JAMA JAMA Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial. 898-907 10.1001/jama.2016.1252 Achieving (...) glycemic control remains a challenge for patients with type 2 diabetes, even with insulin therapy. To assess whether a fixed ratio of insulin degludec/liraglutide was noninferior to continued titration of insulin glargine in patients with uncontrolled type 2 diabetes treated with insulin glargine and metformin. Phase 3, multinational, multicenter, 26-week, randomized, open-label, 2-group, treat-to-target trial conducted at 75 centers in 10 countries from September 2013 to November 2014 among 557

JAMA2016

38. Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide significantly decreases glycated haemoglobin compared with once-daily liraglutide in Japanese patients with type 2 diabetes: 52 weeks of treatment in a randomized phase III study

Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide significantly decreases glycated haemoglobin compared with once-daily liraglutide in Japanese patients with type 2 diabetes: 52 weeks of treatment in a randomized phase III study 26661514 2016 02 09 2016 11 04 2017 02 20 1463-1326 18 3 2016 Mar Diabetes, obesity & metabolism Diabetes Obes Metab Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide significantly decreases glycated haemoglobin compared with once-daily (...) liraglutide in Japanese patients with type 2 diabetes: 52 weeks of treatment in a randomized phase III study. 249-57 10.1111/dom.12602 To examine the efficacy and safety of once-weekly dulaglutide 0.75 mg monotherapy compared with once-daily liraglutide 0.9 mg in Japanese patients with type 2 diabetes (T2D) for 52 weeks. We conducted a phase III, randomized, 52-week (26-week primary endpoint), active- and placebo-controlled trial comparing 492 Japanese patients (dulaglutide, n = 281; liraglutide, n = 141

EvidenceUpdates2016

39. [Insulin degludec/liraglutide: benefit assessment according to §35a Social Code Book V (dossier assessment)]

[Insulin degludec/liraglutide: benefit assessment according to §35a Social Code Book V (dossier assessment)] Insulin degludec/liraglutid – nutzenbewertung gemäß § 35a SGB V [Insulin degludec/liraglutide: benefit assessment according to §35a Social Code Book V (dossier assessment)] Insulin degludec/liraglutid – nutzenbewertung gemäß § 35a SGB V [Insulin degludec/liraglutide: benefit assessment according to §35a Social Code Book V (dossier assessment)] IQWiG Record Status This is a bibliographic (...) record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation IQWiG. Insulin degludec/liraglutid – nutzenbewertung gemäß § 35a SGB V. [Insulin degludec/liraglutide: benefit assessment according to §35a Social Code Book V (dossier assessment)] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 316. 2015 Final publication URL Indexing Status Subject

Health Technology Assessment (HTA) Database.2016

40. [Insulin degludec/liraglutide (new therapeutic indication): benefit assessment according to §35a Social Code Book V]

[Insulin degludec/liraglutide (new therapeutic indication): benefit assessment according to §35a Social Code Book V] Insulin degludec/liraglutid (neues anwendungsgebiet) – nutzenbewertung gemäß § 35a SGB V [Insulin degludec/liraglutide (new therapeutic indication): benefit assessment according to §35a Social Code Book V] Insulin degludec/liraglutid (neues anwendungsgebiet) – nutzenbewertung gemäß § 35a SGB V [Insulin degludec/liraglutide (new therapeutic indication): benefit assessment (...) according to §35a Social Code Book V] IQWiG Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation IQWiG. Insulin degludec/liraglutid (neues anwendungsgebiet) – nutzenbewertung gemäß § 35a SGB V. [Insulin degludec/liraglutide (new therapeutic indication): benefit assessment according to §35a Social Code Book V] Cologne: Institut fuer Qualitaet und

Health Technology Assessment (HTA) Database.2016